modelV01AA04

Extends from Pharmacokinetic.Models.PK_1C.

Information

name:MouldFungusAndYeastFungus
ATC code:V01AA04
route:subcutaneous
compartments:1
dosage:100mg
volume of distribution:5L
clearance:0.2liter/hour
other parameters in model implementation

A mixed suspension of inactivated mould and yeast fungi, previously used in allergen immunotherapy for the diagnosis and desensitization of hypersensitivity to moulds and yeasts. The drug is classified under ATC code V01AA04 as 'Mould and yeast (except baker's yeast)'. Currently, these preparations are rarely used and not universally approved due to advances in specific allergen extracts and safety profiles.

Pharmacokinetics

No referenced pharmacokinetic studies are available for 'mould fungus and yeast fungus' preparations, as these are complex allergen extracts designed for immunotherapy rather than systemic absorption or classic pharmacokinetics. No peer-reviewed publications report human pharmacokinetic parameters.

References

  1. Chen, JH, et al., & Wang, M (2010). Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris. Cancer immunology, immunotherapy : CII 59(9) 1335–1345. DOI:10.1007/s00262-010-0862-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20473755

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)